Repligen Corporation (NASDAQ:RGEN – Free Report) – Research analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for shares of Repligen in a report issued on Thursday, September 11th. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will earn $0.52 per share for the quarter, up from their prior estimate of $0.51. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s FY2026 earnings at $2.11 EPS.
Get Repligen alerts:
Other equities research analysts have also recently issued reports about the company. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Jefferies Financial Group cut their price objective on shares of Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday. Wells Fargo & Company lowered their target price on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, July 30th. Finally, Stephens raised Repligen to an “overweight” rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.67.
View Our Latest Stock Report on RGEN
Repligen Stock Performance
Shares of RGEN opened at $113.54 on Monday. The business’s fifty day moving average price is $120.73 and its 200 day moving average price is $127.58. Repligen has a 12-month low of $102.96 and a 12-month high of $182.52. The stock has a market capitalization of $6.39 billion, a PE ratio of -454.14, a price-to-earnings-growth ratio of 2.09 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.
Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same period in the previous year, the business posted $0.40 EPS. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD boosted its position in Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after buying an additional 430,039 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company’s stock valued at $51,422,000 after buying an additional 400,970 shares during the last quarter. Geneva Capital Management LLC boosted its position in Repligen by 239.6% in the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after buying an additional 343,991 shares during the last quarter. Blue Whale Capital LLP bought a new position in Repligen in the 2nd quarter valued at $35,782,000. Finally, Nuveen LLC bought a new position in Repligen in the 1st quarter valued at $35,536,000. 97.64% of the stock is owned by institutional investors.
Insider Activity
In related news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.20% of the stock is currently owned by corporate insiders.
Repligen Company Profile
(Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Recommended Stories
Five stocks we like better than Repligen
Why is the Ex-Dividend Date Significant to Investors?
Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside
Transportation Stocks Investing
Football Season Is Here and DraftKings Stock Is Surging
The 3 Best Retail Stocks to Shop for in August
RH Stock Slides After Mixed Earnings and Tariff Concerns